首页> 外文OA文献 >Impella RP as a bridge to cardiac transplant for refractory late right ventricular failure in setting of left ventricular assist device
【2h】

Impella RP as a bridge to cardiac transplant for refractory late right ventricular failure in setting of left ventricular assist device

机译:Impella RP作为心脏移植的桥,用于左心室辅助装置的设置中的难治性后右心室失效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Right ventricular (RV) failure remains a major complication after surgical implantation of a left ventricular assist device (LVAD). While the use of a percutaneous RV assist device has been described as a short‐term bridge to recovery in end‐stage heart failure patients with early post‐operative RV failure after index LVAD implant, management of refractory late RV failure remains challenging in these patients. We report the first successful case of extended Impella RP use as a safe and effective bridge to orthotopic heart transplant in an LVAD patient with refractory, haemodynamically significant late RV failure. The Impella RP provided support for 37 days. Haemodynamically intolerant arrhythmia precluded use of inotropic support. No adverse complications related to percutaneous Impella RP support were seen. We also review potential considerations for mechanical circulatory support strategies in this setting: central RV assist device cannulation requires sternotomy incision that can impact subsequent cardiac surgeries, while percutaneous Protek Duo insertion requires adequate vessel size and patency. With an LVAD in situ, veno‐arterial extracorporeal membrane oxygenation was not considered for isolated RV support in this case. The patient is currently over 6 months post‐orthotopic heart transplant.
机译:摘要右心室(RV)失败仍然是左心室辅助装置(LVAD)外科手术植入后的主要复杂性。虽然经皮的RV辅助装置的使用被描述为在术后RV失效的末期心力衰竭患者中恢复的短期桥,但在指数LVAD植入后,难治性后期RV失败的管理在这些患者中仍然具有挑战性。我们报告了延长普拉拉RP的第一个成功案例,作为一种安全有效的桥梁,在具有耐火性,血管动力学显着晚期的RV衰竭的LVAD患者中进行正面心脏移植。 Impella RP为37天提供了支持。血流动力学性激性的心律失常排除使用各渗透性载体。没有看到与经皮速率相关的不良并发症。我们还审查了这种环境中的机械循环支持策略的可能考虑因素:中央RV辅助装置插管需要胸骨切开,可以影响随后的心脏病,而经皮蛋白质二重奏装置需要足够的血管尺寸和通畅。通过原位的LVAD,在这种情况下,不考虑静脉动脉体外膜氧合。患者目前超过6个月后术后心脏移植。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号